Acquisition of NMDL-LCPL in the Netherlands
Eurofins further expands its specialty clinical diagnostics footprint with the acquisition of NMDL-LCPL in the Netherlands
26 February 2018
Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and a key player in the European clinical diagnostics market, announces the acquisition of NMDL-LCPL, a specialized medical testing business providing molecular diagnostics and pathology laboratory services. NMDL-LCPL is comprised of the Nederlands Moleculair Diagnostisch Laboratorium (“NMDL”) and the Leids Cytologisch Pathologisch Laboratorium (“LCPL”).
NMDL-LCPL, with a particular strong presence in the Southwestern part of the Netherlands, serves over 2,000 General Practitioners as well as hospitals, independent treatment centers and other laboratories. Through NMDL it offers molecular diagnostics services, including molecular virology and bacteriology testing. LCPL is the largest pathology laboratory for General Practitioners in the Netherlands and offers advanced pathology services, including cervical cytology and molecular biological tests. NMDL-LCPL’s comprehensive service offering helps its clients to provide effective and quick diagnosis for their patients, playing a crucial role in the early detection of pathological and microbiological disorders.
In 2016, NMDL was proud to be selected as one of the parties to execute the bevolkingsonderzoek (BVO) for the Dutch national cervical cancer screening program. Under this program, NMDL is now routinely performing high-volume molecular diagnostic HPV testing, with a portion of the samples requiring follow-up pathology screening to be performed by LCPL.
The acquisition provides Eurofins a first entry platform for further growth into the clinical diagnostics market in the Netherlands. Together with the recent acquisition of Labo Van Poucke, this transaction significantly expands Eurofins’ portfolio of services offering in clinical diagnostics testing to the benefit of practitioners and patients in the Benelux.
Comment from Dr. Gilles Martin, Eurofins CEO: “We are extremely pleased to welcome NMDL-LCPL, a key player in specialized medical testing, to Eurofins’ family of businesses. This acquisition provides Eurofins with a valuable entry into the Dutch clinical diagnostics market; in return NMDL-LCPL will gain access to the full range of services and capabilities of the Eurofins Group. We look forward to further leveraging our newly-acquired clinical diagnostics platforms in the Benelux region to the benefit of medical practitioners and their patients”.
For more information, please visit www.eurofins.com or contact:
Phone: +32 2 766 1620
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 42 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.